Method for improving affinity of anti-cytokine antibody for antigen, method for producing anti-cytokine antibody, and anti-cytokine antibody

Patent metadata

Field	Value
Publication number	US-2023091175-A1
Application number	US-202217932178-A
Country	US
Kind code	A1
Filing date	Sep 14, 2022
Priority date	Sep 15, 2021
Publication date	Mar 23, 2023
Grant date	—

Abstract

Disclosed is a method for improving an affinity of an anti-cytokine antibody for an antigen, the method comprising: in an anti-cytokine antibody whose electrical characteristic of a complementarity determining region (CDR) is negatively charged, changing at least 3 amino acid residues of light chain framework region 3 to arginine residues or lysine residues, thereby improving an affinity for an antigen as compared with that of an antibody before the at least 3 amino acid residues are changed to arginine residues or lysine residues, wherein the at least 3 amino acid residues comprise residues at least 3 positions selected from the group consisting of positions 63, 65, 67, 70 and 72 of a light chain defined by Chothia method.

First claim

1 . A method for improving an affinity of an anti-cytokine antibody for an antigen, the method comprising:
in an anti-cytokine antibody whose electrical characteristic of complementarity determining regions (CDRs) is negatively charged, changing at least 3 amino acid residues of light chain framework region 3 to arginine residues or lysine residues, thereby improving an affinity for an antigen as compared with that of an antibody before the at least 3 amino acid residues are changed to arginine residues or lysine residues, wherein the electrical characteristic of the CDRsis determined by a following formula:
X =[Number of basic amino acid residues in amino acid sequences of the CDRscontained in one antigen binding site]−[Number of acidic amino acid residues in amino acid sequences of the CDRscontained in one antigen binding site]

wherein when X is −2 or less, the electrical characteristic of the CDRsis negatively charged, when X is −1, 0, or 1, the electrical characteristic of the CDRsis neutral, and when X is 2 or more, the electrical characteristic of the CDRsis positively charged, and the at least 3 amino acid residues comprise residues at least 3 positions selected from the group consisting of positions 63, 65, 67, 70 and 72 of a light chain defined by Chothia method.

2 . A method for producing an anti-cytokine antibody with an improved affinity for an antigen, the method comprising:
in an anti-cytokine antibody whose electrical characteristic of complementarity determining regions (CDRs) is negatively charged, generating an antibody in which at least 3 amino acid residues of light chain framework region 3 are changed to arginine residues or lysine residues; and recovering the antibody generated in the generating, wherein an affinity of the recovered antibody for an antigen is improved as compared with that of an antibody before the at least 3 amino acid residues are changed to arginine residues or lysine residues, the electrical characteristic of the CDRsis determined by a following formula:
X =[Number of basic amino acid residues in amino acid sequences of the CDRscontained in one antigen binding site]−[Number of acidic amino acid residues in amino acid sequences of the CDRscontained in one antigen binding site]

wherein when X is −2 or less, the electrical characteristic of the CDRsis negatively charged, when X is −1, 0, or 1, the electrical characteristic of CDR is neutral, and when X is 2 or more, the electrical characteristic of CDR is positively charged, and the at least 3 amino acid residues comprise residues at least 3 positions selected from the group consisting of positions 63, 65, 67, 70 and 72 of a light chain defined by Chothia method.

3 . The method according to claim 1 , wherein the anti-cytokine antibody is an anti-interleukin antibody.

4 . The method according to claim 3 , wherein the anti-interleukin antibody is an anti-IL-6 antibody, an anti-IL-8 antibody, an anti-IL-12 antibody, or an anti-IL-4 antibody.

5 . The method according to claim 1 , wherein the at least 3 amino acid residues comprise amino acid residues at positions 63, 65 and 67 of the light chain.

6 . The method according to claim 1 , wherein the at least 3 amino acid residues comprise amino acid residues at positions 63, 65, 67 and 70 of the light chain.

7 . The method according to claim 1 , wherein the at least 3 amino acid residues comprise amino acid residues at positions 63, 65, 67, 70 and 72 of the light chain.

8 . An anti-cytokine antibody in which at least 3 amino acid residues of light chain framework region 3 are changed to arginine residues or lysine residues, wherein the anti-cytokine antibody is an antibody whose electrical characteristic of complementarity determining regions (CDRs) is negatively charged, and the electrical characteristic of the CDRsis determined by a following formula:
X =[Number of basic amino acid residues in amino acid sequences of the CDRscontained in one antigen binding site]−[Number of acidic amino acid residues in amino acid sequences of the CDRscontained in one antigen binding site]
wherein when X is −2 or less, the electrical characteristic of the CDRsis negatively charged, when X is −1, 0, or 1, the electrical characteristic of the CDRsis neutral, and when X is 2 or more, the electrical characteristic of the CDRsis positively charged, and the at least 3 amino acid residues comprise residues at least 3 positions selected from the group consisting of positions 63, 65, 67, 70 and 72 of a light chain defined by Chothia method, and an affinity for an antigen is higher than that of an antibody before the at least 3 amino acid residues are changed to arginine residues or lysine residues.

9 . The antibody according to claim 8 , wherein the anti-cytokine antibody is an anti-interleukin antibody.

10 . The antibody according to claim 9 , wherein the anti-interleukin antibody is an anti-IL-6 antibody, an anti-IL-8 antibody, an anti-IL-12 antibody, or an anti-IL-4 antibody.

11 . The antibody according to claim 8 , wherein the at least 3 amino acid residues comprise amino acid residues at positions 63, 65 and 67 of the light chain.

12 . The antibody according to claim 8 , wherein the at least 3 amino acid residues comprise amino acid residues at positions 63, 65, 67 and 70 of the light chain.

13 . The antibody according to claim 8 , wherein the at least 3 amino acid residues comprise amino acid residues at positions 63, 65, 67, 70 and 72 of the light chain.

Assignees

• Sysmex Corp

Inventors

• Egashira Yuriko
• Dixit Shivani
• Tanaka Kazuki
• Maeta Shingo

Classifications

• C07K16/244

  Interleukins [IL] · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• C07K16/247 Primary

  IL-4 · CPC title